Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesValeo Pharma Inc

Valeo Pharma Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.045 CAD 0.00(0%)
Last update at 2024-11-11T14:30:00Z
Market Cap
4.44M

Momentum Score

…

Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.04
Low
0.04
High
52 Week Price Range
0.04
Low
0.39
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.04
Dividend Yield
-
Revenue TTM
53.38M
Revenue Per Share
0.61
Gross Profit TTM
8.52M
Debt / Equity
-
ROE
-1600.41%
Net Debt
56.26M
ROCE
-80.25%
Diluted EPS TTM
-0.37

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Type yearly yearly yearly yearly yearly
Date 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Income before tax -26.92M -14.23M -4.76M -3.62M -2.40M
Net income -25.75M -14.23M -4.76M -3.62M -2.44M
Selling general administrative 25.04M 16.26M 5.46M 5.05M 3.22M
Gross profit 6.28M 3.96M 1.38M 1.40M 0.83M
Reconciled depreciation 1.42M 0.74M 0.42M 0.14M -
Ebit -16.80M -11.38M -4.25M -3.74M -
Ebitda -19.04M -12.13M -3.74M -3.41M -
Operating income -19.60M -12.82M -4.34M -3.74M -2.28M
Interest expense 6.46M 1.36M 0.60M 0.07M 0.00M
Tax provision -1.17M 0.00M 0.00M 0.00M 0.04M
Interest income 7.11M 1.38M 0.42M 0.07M 0.17M
Net interest income -6.33M -1.39M -0.61M -0.13M -
Income tax expense -1.17M - - - -
Total revenue 27.75M 13.56M 7.47M 6.58M 4.38M
Total operating expenses 46.85M 26.25M 11.77M 10.31M -
Cost of revenue 21.46M 9.60M 6.09M 5.18M 3.55M
Total other income expense net -1.48M -0.15M 0.15M 0.26M -
Net income from continuing ops -25.75M -14.23M -4.76M -3.62M -
Net income applicable to common shares -25.75M -14.23M -4.76M -3.62M -2.44M
Breakdown 2023-10-31 2022-10-31 2021-10-31 2020-10-31 2019-10-31
Type yearly yearly yearly yearly yearly
Date 2023-10-31 2022-10-31 2021-10-31 2020-10-31 2019-10-31
Total assets 41.21M 58.27M 21.03M 10.96M 5.81M
Intangible assets 13.30M 15.48M 6.54M 4.95M 3.86M
Total liab 81.54M 76.11M 18.98M 7.89M 5.83M
Total stockholder equity -40.34M -17.85M 2.05M 3.07M -0.02M
Deferred long term liab - 1.87M 2.81M 2.75M 1.88M
Other current liab - 4.29M 2.75M 0.72M 0.60M
Common stock - 26.36M 24.62M 15.02M 8.83M
Capital stock 31.70M 26.36M 24.62M 15.02M 8.83M
Retained earnings -82.26M -54.46M -28.71M -14.48M -9.72M
Other liab - 0.13M 0.87M 0.42M 0.35M
Other assets - 1.87M 2.81M 2.75M 1.88M
Cash 7.50M 22.50M 2.04M 2.84M 0.34M
Total current liabilities 20.27M 15.34M 15.33M 4.28M 4.48M
Net debt 56.26M 37.77M 4.42M 0.13M 0.67M
Short term debt - 0.74M 0.00M 0.00M 0.00M
Short long term debt 4.60M 0.74M 4.85M - -
Other stockholder equity - 5.84M 3.75M 0.91M 0.27M
Property plant equipment - 2.25M 2.14M 0.60M 0.30M
Total current assets 25.24M 40.53M 12.35M 5.41M 1.65M
Net tangible assets - -31.46M -1.68M 0.87M -2.00M
Net receivables 6.42M 5.43M 1.80M 1.22M 0.61M
Long term debt 59.16M 59.53M 1.60M 2.97M 1.00M
Inventory 10.25M 9.98M 7.67M 0.88M 0.56M
Accounts payable 3.99M 3.74M 7.32M 3.38M 3.84M
Non current assets total 15.96M 17.74M 8.68M 5.55M 4.16M
Capital lease obligations 1.40M 1.17M 1.21M 0.29M -
Long term debt total - 60.65M 2.77M 3.20M 1.00M
Breakdown 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Type yearly yearly yearly yearly yearly
Date 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Investments -6.89M -3.46M -1.41M -0.92M -
Change to liabilities -4.02M 6.42M -0.68M 0.96M -
Total cashflows from investing activities -6.89M -3.46M -1.41M -0.92M 0.06M
Net borrowings 19.67M 3.52M 2.75M 0.95M -
Total cash from financing activities 54.99M 15.10M 9.21M 3.55M 1.28M
Change to operating activities -0.03M -0.27M -0.23M -0.20M -
Net income -25.75M -14.23M -4.76M -3.62M -2.44M
Change in cash 20.46M -0.79M 2.50M 0.32M 0.01M
Begin period cash flow 2.04M 2.84M 0.34M 0.01M -
End period cash flow 22.50M 2.04M 2.84M 0.34M 0.01M
Total cash from operating activities -28.50M -12.31M -5.30M -2.31M -1.33M
Issuance of capital stock 0.00M 11.50M 7.24M 3.11M -
Depreciation 1.13M 0.48M 0.31M 0.10M 0.04M
Other cashflows from investing activities - - 0.00M 0.02M 0.39M
Change to inventory -3.81M -6.98M -0.53M -0.47M -
Change to account receivables -3.63M -0.58M -0.71M 0.35M -
Sale purchase of stock 0.39M 13.22M 7.24M 3.11M -
Other cashflows from financing activities 34.93M 1.20M -0.24M 0.02M -0.07M
Change to netincome 7.31M 2.59M 1.18M 0.51M -
Capital expenditures 0.36M 0.90M 0.06M 0.03M 0.32M
Change in working capital -11.48M -1.41M -2.14M 0.65M 0.79M
Stock based compensation 0.94M 1.00M 0.47M 0.33M -
Other non cash items 3.54M 1.06M 0.50M 0.09M -
Free cash flow -35.39M -15.78M -6.70M -3.25M -

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VPH
Valeo Pharma Inc		 -
-%		 0.04 - - 0.08 71.69 1.26 -4.42
CURA
Curaleaf Holdings Inc.		 -0.74
5.20%		 13.49 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc		 0.31
2.72%		 11.72 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc		 0.16
3.36%		 4.92 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 0.41
11.02%		 4.13 - 1000.00 1.28 0.53 1.08 -2.30

Profile*

Valeo Pharma Inc

Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.

16667 Hymus Boulevard, Kirkland, QC, Canada, H9H 4R9

514 694 0150

https://www.valeopharma.com

70

Name Title Year Born
Mr. Steven Saviuk CA Vice Chairman & CEO 1959
Mr. Luc Mainville M.B.A, M.B.A. Sr. VP & CFO 1964
Mr. Guy-Paul Allard VP of Legal Affairs & Corp. Sec. NA
Mr. Frederic Dumais Director of Communications & Investor Relations NA
Mr. Kyle Steiger Sr. VP & Chief Commercial Officer NA
Mr. Jean Francois Fournier Head of Ophthalmology Bus. Unit NA
Mr. Kyle Steiger Senior VP & Chief Commercial Officer NA
Mr. Al Moghaddam B. Com. Cma Chief Executive Officer 1967
Mr. Pascal Tougas Chief Financial Officer NA
Mr. Guy-Paul Allard VP of Legal Affairs & Corporate Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…